4-[(2-Cyclopentyl-6,7-dichloro-2,3-dihydro-2-methyl-1-oxo-1H-inden-5-yl)oxy]butanenitrile | 119897-72-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: 4-[(2-Cyclopentyl-6,7-dichloro-2,3-dihydro-2-methyl-1-oxo-1H-inden-5-yl)oxy]butanenitrile
• 英文别名: 4-(6,7-dichloro-2-cyclopentyl-2-methyl-1-oxo-indan-5-yloxy)-butyronitrile；4-[(6,7-dichloro-2-cyclopentyl-2-methyl-1-oxo-3H-inden-5-yl)oxy]butanenitrile
• CAS: 119897-72-2
• 化学式: C₁₉H₂₁Cl₂NO₂
• 分子量: 366.287
• InChiKey: XPBNQUXLZGMMHD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.5
• 重原子数：
  24
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  50.1
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-[(2-Cyclopentyl-6,7-dichloro-2,3-dihydro-2-methyl-1-oxo-1H-inden-5-yl)oxy]butanenitrile 生成 4-[(6,7-dichloro-2-cyclopentyl-2-methyl-1-oxo-3H-inden-5-yl)oxy]butanimidamide
  参考文献：
  名称：

  CRAGOE, EDWARD J. (JR);WOLTERSDORF, OTTO W. (JR)

  摘要：

  DOI：
• 作为产物：
  描述：

  2-cyclopentyl-2-methyl-5-hydroxy-6,7-dichloro-1-indanone 、 4-溴丁腈 在 potassium carbonate 作用下， 以 丙酮 为溶剂， 生成 4-[(2-Cyclopentyl-6,7-dichloro-2,3-dihydro-2-methyl-1-oxo-1H-inden-5-yl)oxy]butanenitrile
  参考文献：
  名称：

  [EN] INDANONE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS
  [FR] FACTEURS DE POTENTIALISATION D'INDANONE DE RÉCEPTEURS MÉTABOTROPIQUES DE GLUTAMATES

  摘要：

  本发明涉及一类潜在激活代谢型谷氨酸受体的化合物，包括mGluR2受体，这些化合物在治疗或预防与谷氨酸功能障碍相关的神经系统和精神疾病以及代谢型谷氨酸受体参与的疾病中具有用途。该发明还涉及包含这些化合物的药物组合物以及这些化合物和组合物在预防或治疗代谢型谷氨酸受体参与的疾病中的用途。

  公开号：

  WO2006015158A1

文献信息

• [EN] INDANONE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS<br/>[FR] FACTEURS DE POTENTIALISATION D'INDANONE DE RÉCEPTEURS MÉTABOTROPIQUES DE GLUTAMATES
  申请人：MERCK & CO INC

  公开号：WO2006015158A1

  公开（公告）日：2006-02-09

  The present invention is directed to compounds which are potentiators of metabotropic glutamate receptors, including the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.

  本发明涉及一类潜在激活代谢型谷氨酸受体的化合物，包括mGluR2受体，这些化合物在治疗或预防与谷氨酸功能障碍相关的神经系统和精神疾病以及代谢型谷氨酸受体参与的疾病中具有用途。该发明还涉及包含这些化合物的药物组合物以及这些化合物和组合物在预防或治疗代谢型谷氨酸受体参与的疾病中的用途。
• Substituted amidinoalkoxy and amidinoalkylamino indanones and salts
  申请人：Merck & Co., Inc.

  公开号：US04775695A1

  公开（公告）日：1988-10-04

  This invention relates to novel substituted amidinoalkoxy and amidinoalkylamino indanones and salts thereof. The compounds are useful for the treatment and prevention of injury to the brain and of edema due to head trauma, stroke (particularly ischemic), arrested breathing, cardiac arrest, Reye's syndrome, cerebral thrombosis, cerebral embolism, the neurological problems caused by AIDS, cerebral hemorrhage, cerebral tumors, encephalomyelitis, spinal cord injury, hydrocephalus, post-operative brain injury trauma, edema due to cerebral infections, various brain concussions, and elevated intracranial pressure.

  本发明涉及新型取代的酰胺基烷氧基和酰胺基烷基氨基茚酮及其盐。这些化合物可用于治疗和预防由头部创伤、中风（尤其是缺血性中风）、呼吸骤停、心脏骤停、Reye综合症、脑血栓形成、脑栓塞、艾滋病引起的神经问题、脑出血、脑肿瘤、脑脊髓炎、脊髓损伤、脑积水、手术后脑损伤创伤、脑感染引起的水肿、各种脑震荡和颅内压升高所引起的水肿。
• Indanone Potentiators of Metabotropic Glutamate Receptors
  申请人：Pinkerton Anthony B.

  公开号：US20080312286A1

  公开（公告）日：2008-12-18

  The present invention is directed to compounds which are potentiators of metabotropic glutamate receptors, including the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.

  本发明涉及增强代谢型谷氨酸受体（包括mGluR2受体）的化合物，用于治疗或预防与谷氨酸功能障碍有关的神经和精神障碍以及涉及代谢型谷氨酸受体的疾病。本发明还涉及包含这些化合物的制药组合物以及在预防或治疗涉及代谢型谷氨酸受体的疾病中使用这些化合物和组合物。
• CRAGOE, EDWARD J. (JR);WOLTERSDORF, OTTO W. (JR)
  作者：CRAGOE, EDWARD J. (JR)、WOLTERSDORF, OTTO W. (JR)

  DOI：——

  日期：——
• INDANONE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS
  申请人：Merck & Co., Inc.

  公开号：EP1773792A1

  公开（公告）日：2007-04-18